Fig. 4: Treatment with lanabecestat in the AMARANTH trial decreases significantly CDR-SOB scores for the slow but not the rapid progressive individuals. | Nature Communications

Fig. 4: Treatment with lanabecestat in the AMARANTH trial decreases significantly CDR-SOB scores for the slow but not the rapid progressive individuals.

From: AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial

Fig. 4

A Mean CDR-SOB over time for Slow, Rapid, and All Progressive individuals (sample size: Supplementary Table S3) in the placebo (gray dashed), lanabecestat 20 mg (blue), and lanabecestat 50 mg (purple). Error bars indicate the standard error of the mean across individuals (SEM). B Box plots of change in CDR-SOB (week 104 minus week1) for Slow, Rapid, and All Progressive (sample size: Supplementary Table S3). Black lines in the box plots indicate the median for placebo (gray), lanabecestat 20 mg (blue), and lanabecestat 50 mg (purple), the solid black box represents the 25th to 75th percentile, the black vertical lines represent the range of the data, and black circles indicate outliers. Asterisks indicate significant differences between slow progressive individuals in the 50 mg treatment group vs. placebo. Source data are provided as a Source Data file.

Back to article page